Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent Sang Joon ShinJee Won HwangHyun Cheol Chung PRECLINICAL STUDIES 27 April 2012 Pages: 1 - 13
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer J. RodrÃguez-PascualP. ShaM. Hidalgo PRECLINICAL STUDIES 07 June 2012 Pages: 14 - 19
Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells Donna M. CartledgeRita ColellaRobert W. Mason PRECLINICAL STUDIES 02 May 2012 Pages: 20 - 29
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines Brigette B. Y. MaVivian W. Y. LuiAnthony T. C. Chan PRECLINICAL STUDIES 08 May 2012 Pages: 30 - 38
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines Jodi A. MuscalKathleen A. ScorsoneStacey L. Berg PRECLINICAL STUDIES 06 June 2012 Pages: 39 - 45
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer Nilesh A. PatankarDawn WaterhouseMarcel B. Bally PRECLINICAL STUDIES 22 May 2012 Pages: 46 - 58
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study Anne SudakaAntoine SusiniGérard Milano PRECLINICAL STUDIES 20 June 2012 Pages: 59 - 65
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases Teresa G. GrandaDavid CebriánJames R. Bischoff PRECLINICAL STUDIES 24 May 2012 Pages: 66 - 76
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors Christina M. AnnunziataElise C. KohnRobert Lechleider PHASE I STUDIES Open access 28 February 2012 Pages: 77 - 84
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer Sil KordesDick J. RichelJohanna W. Wilmink PHASE I STUDIES Open access 25 February 2012 Pages: 85 - 91
Phase I trial of dasatinib and ixabepilone in patients with solid tumors P. HerbolsheimerR. KapoorS. M. Swain PHASE I STUDIES 06 March 2012 Pages: 92 - 98
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma Thomas YauP. N. ChengRonnie T. Poon PHASE I STUDIES Open access 17 March 2012 Pages: 99 - 107
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours Yasuhito FujisakaYusuke OnozawaNarikazu Boku PHASE I STUDIES 14 March 2012 Pages: 108 - 114
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer A. DasariL. GoreD. R. Camidge PHASE I STUDIES 14 March 2012 Pages: 115 - 125
Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent Matthew BurgeAlessandra B. FrancesconiJason D. Lickliter PHASE I STUDIES 27 March 2012 Pages: 126 - 135
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer Glen J. WeissRoss C. DonehowerScott McKane PHASE I STUDIES 11 April 2012 Pages: 136 - 144
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma Christopher W. RyanChacon MatiasM. L. Keohan PHASE II STUDIES 27 April 2012 Pages: 145 - 151
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer Keun Seok LeeIn Hae ParkJungsil Ro PHASE II STUDIES 05 May 2012 Pages: 152 - 159
Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer Amanda F. BakerDenise J. RoeSetsuko K. Chambers PHASE II STUDIES 13 May 2012 Pages: 160 - 166
Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005 J. T. HartmannS. BauerF. Mayer PHASE II STUDIES 05 July 2012 Pages: 167 - 174
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer Christian ManegoldJohan VansteenkisteJoachim von Pawel PHASE II STUDIES Open access 03 July 2012 Pages: 175 - 182
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy Yong Sang HongJeeyun LeeTae Won Kim PHASE II STUDIES 11 July 2012 Pages: 183 - 191
The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice Valentina RapozziSonia ZorzetLuigi E. Xodo SHORT REPORT 12 June 2012 Pages: 192 - 199
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications Antonio Garcia-GomezEnrique M. OcioMercedes Garayoa SHORT REPORT 07 July 2012 Pages: 200 - 205
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel Alexander N. WeinShihui LiuStephen H. Leppla SHORT REPORT 28 July 2012 Pages: 206 - 212
Investigational agents in development for the treatment of ovarian cancer Shannon N. WestinThomas J. HerzogRobert L. Coleman REVIEW 04 June 2012 Pages: 213 - 229
Development of artemisinin compounds for cancer treatment Henry C. LaiNarendra P. SinghTomikazu Sasaki REVIEW 31 August 2012 Pages: 230 - 246